BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35797633)

  • 1. 18F-FES PET/CT for Characterization of Brain and Leptomeningeal Metastasis in Double Primary Cancer Patient.
    Lee Y; Yoo IR; Ha S
    Clin Nucl Med; 2022 Aug; 47(8):e554-e556. PubMed ID: 35797633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.
    Boers J; Schröder CP; Hospers GAP; de Vries EFJ; Glaudemans AWJM
    Clin Nucl Med; 2021 Mar; 46(3):e165-e167. PubMed ID: 33181752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracranial Leptomeningeal Carcinomatosis from Breast Cancer Detected on 18F-FDG PET.
    Carra BJ; Clemenshaw MN
    J Nucl Med Technol; 2015 Sep; 43(3):227-8. PubMed ID: 25655343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
    Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
    Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-Choline PET/CT in Leptomeningeal Breast Cancer Metastases.
    Cuppari L; Reccia P; Burei M; Cervino AR; Evangelista L
    Clin Nucl Med; 2019 Feb; 44(2):e96-e97. PubMed ID: 30516668
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy and safety of 16α-[
    Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
    Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
    Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Validity of 16α-[
    van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
    J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
    J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
    Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
    Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [
    Ryu J; Jeong JH; Moon DH; Lee DY
    Nucl Med Mol Imaging; 2022 Apr; 56(2):105-109. PubMed ID: 35464670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
    Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
    Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
    Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
    J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.